Introduction. Progesterone is becoming universally accepted for preventing recurrent spontaneous preterm delivery. There is, however, poor consensus on the effective types and doses of progesterone to be used. Despite the encouraging available research, the role of oral micronized progesterone has not yet been thoroughly investigated. Material and methods. We randomized 212 singleton pregnancies with past history of spontaneous preterm delivery at <37 weeks, into a progesterone group (receiving 100 mg oral micronized progesterone, six-hourly, starting at 14-18 weeks until 37 weeks or delivery) and an identical placebo group. The rate of spontaneous preterm delivery was the primary outcome. Secondary outcomes included gestational age at birth and admission to neonatal intensive care units. Results. The progesterone group delivered at a later gestational age, and needed longer tocolysis-todelivery intervals (35.4 weeks vs. 33.9 weeks, p = 0.01, and 87 days vs. 36 days, p < 0.001, respectively). The relative risk of spontaneous preterm delivery was 0.7 (95% confidence interval 0.54-0.92, p = 0.01), and the number needed-totreat to prevent one case of spontaneous preterm delivery was 5 (95% confidence interval 3-20). The two groups had similar rates of operative delivery and postpartum complications. Progesterone was associated with mild maternal dizziness (29.1% vs. 9.8%, p = 0.002), somnolence (41.6% vs. 19.7%, p = 0.002), and vaginal dryness (20.8% vs. 8.7%, p = 0.03), lower neonatal mortality rates (7.3% vs. 25.2%, p < 0.001), and shorter neonatal intensive care unit admissions (p = 0.008). Conclusion. Oral micronized progesterone is effective in preventing spontaneous preterm delivery. The additional advantages of oral administration, affordability, and high safety profile make it worth recommending, at least for further research.
Introduction
Worldwide, preterm birth is becoming a major problem. With its rising incidence over the last few decades (1) , it currently represents the leading cause of neonatal mortality and long-term morbidity (2) . It also remains a considerable financial burden for both governments and individuals. This situation is further complicated in developing countries because of an even higher incidence (3), associated with poor and limited neonatology services.
So far, six interventions have proven to help to reduce the incidence of preterm delivery and/or neonatal complications of functional prematurity (4) : judicious use of fertility treatments and preference for single embryo transfers in in vitro fertilization to reduce multiple pregnancies; reducing the rate of elective delivery in the late preterm and early term period (36-39 weeks of gestation); providing dedicated preterm birth prevention clinics; smoke-free legislation and advising against smoking during pregnancy; and, last but not least, cervical cerclage and progesterone supplementation (5, 6) .
Preterm labor is at least partly related to an untimely decline in the progesterone effect (2) . This is probably due to changes at the level of progesterone receptors and their transcriptional activity (7) , rather than any real decline in the circulating progesterone level (8) . Furthermore, the effectiveness of progesterone, namely, the weekly administered intramuscular 17-alpha-hydroxyprogesterone-caproate (17OHP-C), was proven to be inversely proportional to the gestational age at which it was started (9) .
The most recent Cochrane systematic review showed that 17OHP-C and the vaginally administered progesterone significantly reduced the rate of spontaneous preterm delivery (SPD), perinatal mortality, neonatal morbidity and low birthweight [relative risk (RR) 0.64, 0.55, 0.74 and 0.92, respectively] when compared with placebo (10) . The vaginally administered progesterone has become the most widely effective alternative in preventing preterm birth (2, 11, 12) . However, it is poorly accepted by some women and is frequently associated with an unpleasant vaginal discharge (13) . On the other hand, 17OHP-C was only proven effective among women with singleton gestations and a history of spontaneous preterm birth (14) . Otherwise, it was shown to be ineffective in other high-risk groups such as women with an isolated short cervical length or those with multiple pregnancies (2, 15) .
It seems surprising that over the last four decades the oral alternative was the first and yet least studied route for the prevention of preterm labor (16, 17) . For instance, whereas the best evidence so far has supported the value of vaginal progesterone, and 17OHP-C seems to be losing part of its initial attraction (2), research into the role of oral micronized progesterone (OMP) seems to be lagging behind. What remains now, according to Cochrane, is more research into the true value (AE the most effective dose) for every available route of progesterone administration. In fact, the Cochrane survey concludes: "Further trials are still required to assess the optimal timing, mode of administration and dose of administration of progesterone therapy" (10) . Thus, the current situation with the oral route is not that of a proven absence of value, but rather of a scarcity of relevant research.
Material and methods
The current study was a single-center, prospective, double-blind, randomized placebo-controlled trial (RCT), registered with the US FDA clinicaltrials.gov, NCT02571296. It was conducted at Ain Shams University Maternity Hospital, Cairo, from June 2015 to December 2016. The research protocol was approved by the departmental ethics committee on 15 June 2015.
The study randomized 212 patients, with a history of prior SPD, into a progesterone group (n = 106) receiving six-hourly 100 mg OMP capsules (Utrocare â , October Pharma, Sixth of October city, Egypt) and a placebo group (n = 106) receiving identical oral capsules (made by the same company: October Pharma). The treatment course was to be stopped at 37 weeks. Patients were selected for randomization if they had a singleton live pregnancy, a sure and reliable gestational age of 14-18 weeks, and a past history of at least one SPD at <37 weeks. Exclusion criteria included established persistent uterine contractions, progesterone use in the current pregnancy (ongoing or past), active liver disease, obstetric, medical or surgical complications indicating delivery, presence of fetal anomalies incompatible with life, and preterm premature rupture of membranes (PPROM). We followed the example of some previous studies in allowing for cervical cerclage among our recruited cases (6, (18) (19) (20) (21) . This, ethically, aimed to leave the women in the control group with some sort of protection against preterm delivery. All of the included women gave their informed consent prior to their inclusion in the study. Each patient was offered the choice of using vaginal progesterone as an alternative to participating in this study. The authors declare that they had no conflicts of interest.
The required sample size was calculated using the effect size calculated based on the results of Rai et al. (22) , where the difference between the rate of SPD among the study and placebo groups (39.2% vs. 59.5%, respectively) was 20.3. Using the equation of sample size calculation derived from Fox et al. (23) , with a power of 80% (beta error, 0.2) and a confidence level of 95% (alpha error, 0.05), and accounting for an expected drop-out rate of
Key Message
Women on oral micronized progesterone were significantly less frequently admitted for preterm delivery. They delivered at a later gestational age. Neonates of the placebo group had higher morbidity/mortality rates and longer duration of admission to neonatal intensive care units. 15%, the calculation for each of the two arms was as follows: where N = Sample size (in each arm); K = Constant, which varies according to a and b values, here K = 7.9; D = percentage increase to compensate for the drop-out rate, here D =115%; p1 and p2 = the rate of preterm delivery on oral progesterone vs. placebo in a previously published similar RCT (22) . This gave a calculated sample size of 106 patients in each arm.
All patients who were fit for admission into the study blindly selected one of the numbered sealed opaque identical bags containing either the active medicine or an identical placebo. The code for the 212 bag numbers was a confidential computer-generated random number list (generated using MedCalc © Software bvba, Ostend, Belgium). The list was left in a sealed envelope with the head nurse of the antenatal clinic until the end of data collection. Upon inclusion, patients underwent complete clinical assessment and vaginal sterile speculum examination for any cervical dilation, effacement, or ruptured membranes. Obstetric ultrasonography was done to assess gestational age, amniotic fluid volume, fetal weight, placental position, and exclude fetal anomalies. Treatment (progesterone vs. placebo) was started upon inclusion at 14-18 weeks. Progesterone levels were checked at 20 and 28 weeks. Transvaginal ultrasound was done at 20 weeks for cervical length assessment. As per our hospital protocol, emergency/rescue cervical cerclage was done for those with a cervical length <15 mm, and follow-up scans were continued till 28 weeks (twice monthly for those with a cervical length of 20-25 mm and weekly for shorter cervical lengths).
Patients were followed up regularly by phone calls, at twice-monthly intervals, to ensure adherence to the study protocol. They were asked to return to the clinic/hospital for their antenatal care or in the case of persistent uterine contractions, rupture of membranes or vaginal bleeding. Women admitted to hospital, for tocolysis or any obstetric/medical complication, were instructed to continue their medication.
The primary outcome of the study was the incidence of preterm delivery (gestational age <37 weeks). Secondary outcomes included the neonatal birthweight, admission (and duration of stay) into neonatal intensive care units, neonatal mortality rate, and the incidence of mid-trimester miscarriages. The incidence (and gestational age) of preterm premature rupture of membranes, or obstetric complications (chorioamnionitis, postpartum sepsis and intra-or postpartum hemorrhage) were recorded. Serum progesterone levels as well as adverse effects of the study medicine (such as dizziness, constipation, sleepiness, or vaginal dryness) were checked at least once during each of the second and third trimesters. The degree of side effects to progesterone was assessed using an objective scaling scoring system, i.e. 0 (no symptoms), 1 (mild, not requiring any change in lifestyle), 2 (moderate, needing to be controlled with another method to become accepted), 3 (severe, not controlled but still acceptable), 4 (severe, not controlled and not acceptable, mandating to stop treatment).
The results were collected, tabulated and then analyzed using Medcalc © software (www.medcalc.org). Categorical data (proportions) were expressed as frequency and percentage. They were compared using the Chi-square test or Fisher's exact test for quantitative variables of small sample size. Numerical data were presented as mean and standard deviation. They were compared using Student ttest when comparing continuous variables with a normal distribution, or Mann-Whitney U-test for non-parametric data. Relative risk and number-needed-to-treat (NNT) were calculated, using the same software, based on the absolute risks of the treatment and control groups and the resulting absolute risk reduction. The probability of error (p-value) was considered significant when <0.05.
Results
Of 316 women assessed for eligibility, 84 were excluded because they did not meet the inclusion criteria and 20 others declined to participate. The remaining 212 women were randomized and started the study. A total of seven patients were lost during the follow-up process due to loss of contact, three in the progesterone group and four in the placebo group. Seven patients in the progesterone group miscarried, as opposed to 11 controls (6.8% vs. 10.8%, respectively, p = 0.31). The final outcome data were thus available for 96 women in the progesterone group and 91 women in the placebo group (Figure 1 ). The two groups (106 women each) matched well for baseline characteristics (Table 1, Table S1 ). During the current pregnancy, their cervical lengths were statistically similar (25.7 AE 8.3 in the progesterone group, ranging from 13 to 40 mm vs. 23.9 AE 9.7 in the placebo group, ranging between 13 and 44 mm, p = 0.17; Table 2 ). The two groups underwent cervical cerclage at similar rates, whether electively at the end of the first trimester or emergency/rescue procedures at ≥20 weeks (Table 2) .
Progesterone levels were checked at 20 and 28 weeks. They were obviously significantly higher in the progesterone group and even higher during the third trimester ( Table 2) .
The rates of operative delivery or maternal postpartum complications were statistically similar among the two study groups (Table 3 ). Gestational diabetes mellitus was detected in two women in the placebo group and one in the progesterone group (p = 0.51). No women developed elevated liver enzymes during pregnancy. Three women in the progesterone group and two in the placebo group developed mild uncomplicated gestational hypertension (p = 0.66).
On the other hand, the placebo group had higher rates of neonatal complications (mainly low birthweight and respiratory distress syndrome; Table 4 ), longer duration of admission to neonatal intensive care units (NICU) and higher neonatal mortality rates (Table 4) . Their rates of developing intracranial hemorrhage and necrotizing enterocolitis were higher than the progesterone group, but did not reach statistical significance (Table 4) .
Women receiving progesterone treatment were more likely to complain of dizziness, somnolence, and vaginal dryness (Table 5) . However, these symptoms were mostly Data are given in mean AE standard deviation or n (%). PPROM, preterm premature rupture of membranes. Data are given in mean AE standard deviation or n (%). classified as mild or moderate (grades 1 and 2). Grade 3 constipation and somnolence were reported, respectively by six and seven women in the progesterone group vs. four and two women in the placebo group (Table 5 , p = 0.58 and 0.11, respectively). No women stopped their medication due to side effects. Last, but not least, women of the progesterone group were less likely to be admitted for tocolysis or preterm deliveries (Table 3) . Women in this group delivered at a significantly higher gestational age, and those who needed tocolysis had significantly longer tocolysis-to-delivery intervals ( Table 3 ). The progesterone group had a higher cumulative percentage of undelivered cases per gestational week (Figure 2 ). The RR of delivering preterm was 0.7, with a 95% CI of 0.54-0.92 (p = 0.01), and the NNT to prevent one case of preterm delivery was 5.28, with a 95% CI of 3.03-20.35.
Discussion
Although most of the research published so far on the use of progesterone for preventing prematurity focused on the vaginal and intramuscular progesterone, the oral alternative was the route studied first (16, 17) . With the advantages of a cheaper price and an easier mode of administration, this route has a higher potential for acceptability in the Egyptian community. In Egypt at present, a weekly course of OMP (100 mg qid) costs the equivalent of 1.5 US dollars (USD), whereas vaginal progesterone (200 mg bid) costs 2.75 USD, and 17OHP-C 250 mg twice weekly (although it has lately been difficult to find in the Egyptian market) costs 1.7 USD. Unfortunately, and surprisingly enough, very few studies on the value of OMP in preventing prematurity could be identified on literature review. The number is so small that the Cochrane database called for more research on this topic to obtain more concrete answers concerning the value and dose of each and every route of progesterone administration (10) .
The oldest study on OMP came from France. That a multicenter placebo-controlled trial included 57 patients admitted with preterm uterine contractions (16) . Its results were quite encouraging, as contractions were aborted in about 80% among the treatment group as opposed to only 42% among the placebo group who had bed rest only. A second trial, French as well, was an RCT of 44 patients admitted for tocolysis at 32-35 weeks (17) . It also had encouraging results. The dose, duration, and cost of using tocolysis were all significantly reduced in the progesterone group.
Twenty years later, a double-blind RCT randomized 150 women with history of prior preterm delivery to either placebo or 12-hourly 100 mg OMP, starting at 18-24 weeks until delivery or 36 weeks (22) . It showed very encouraging Rest of the data are given in number of cases and percentage (%). (22) . It also carried some defects or drawbacks related to the study design, all of which were corrected in the current study. For instance, we have the advantages of earlier patient recruitment, equal cervical length and progesterone levels between the two study arms, as well as documented insignificant differences in the number and gestational age of previous SPD, and the rate of cervical cerclage in the current pregnancy. Then came the American double-blind RCT of Glover et al. which used a different dose of OMP (400 mg once daily at bedtime) (24) . They still had the same drawback of recruiting a small number of cases (33 women), leading to the failure of their results to reach statistical significance. They concluded that further studies are still required in this field. In 2014, Choudhary et al. published their 90-patient study on the significant value of OMP in the tertiary prevention of preterm birth among patients who had successful tocolysis (25) . Very recently, another study (21) was published, unfortunately still with a very low number of cases. It assigned 10-15 cases only in each of the following four groups: dydrogesterone, OMP, vaginal progesterone and 17OHP-C (21). The patients started progesterone supplementation (400 mg/day) as late as 24 weeks in pregnancy and did not have any history of prior preterm delivery. It may thus not be surprising to see such research reaching different conclusions and suggesting no value for oral medicines in preventing preterm delivery.
The scarcity of relevant research on the use of OMP to prevent SPD is further complicated by the variable doses used in the published studies, ranging between 100 mg 12-hourly (22) , 100 mg six-hourly (16, 17) , 200 mg (25) , and 400 mg once daily (21, 24) .
The best strategy to study the role of any progesterone in preventing preterm birth is to target patients with recurrent SPD. This was followed in the current study as well as those of Rai et al. and Glover et al. (21, 24) . It reduces the risk of false-positive results, since the rate of recurrent preterm birth may be as high as 22.5%, representing a 2.5-fold increase in the risk of prematurity, as opposed to that among women with no previous SPD (26) . We acknowledge the fact that approximately 75% of our study population had undergone cervical cerclage. However, we are confident this did not affect our final conclusions, since the rate of cervical cerclage was similar in the two study groups.
Traditionally, the bioavailability of orally administered progesterone was questionable, due to hepatic first-pass metabolism (27) . This may at least partly explain why dydrogesterone, a synthetic oral progesterone, was recently found ineffective in preventing SPD (21, 28) . However, micronization increases the bioavailability of oral progesterone to the point where serum therapeutic levels may be attained (29) . The current results support this claim.
Our findings support the previous opinions that OMP is well tolerated and carries no serious or disturbing side effects (22, 24) . The oral route of administration obviates the discomfort associated with intramuscular injections and even vaginal suppositories. This is further supported by our encouraging results regarding the RR and NNT associated with using OMP to prevent preterm delivery, when compared with those obtained for vaginal progesterone (RR of 0.89 for prevention of SPD <37 weeks, and 0.79 for preventing SPD <36 weeks with a NNT of 15) in a recent meta-analysis (11).
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